nodes	percent_of_prediction	percent_of_DWPC	metapath
Maprotiline—Sertraline—CYP3A4—bone cancer	0.00996	0.553	CrCbGaD
Maprotiline—Vascular purpura—Doxorubicin—bone cancer	0.00254	0.00381	CcSEcCtD
Maprotiline—Atomoxetine—CYP3A4—bone cancer	0.00251	0.139	CrCbGaD
Maprotiline—Cerebrovascular accident—Epirubicin—bone cancer	0.00251	0.00376	CcSEcCtD
Maprotiline—Convulsion—Cisplatin—bone cancer	0.00249	0.00375	CcSEcCtD
Maprotiline—Ataxia—Methotrexate—bone cancer	0.00247	0.0037	CcSEcCtD
Maprotiline—Osteoarthritis—Epirubicin—bone cancer	0.00245	0.00369	CcSEcCtD
Maprotiline—Anxiety—Cisplatin—bone cancer	0.00244	0.00367	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.00243	0.00366	CcSEcCtD
Maprotiline—Hot flush—Doxorubicin—bone cancer	0.00243	0.00365	CcSEcCtD
Maprotiline—Liver function test abnormal—Methotrexate—bone cancer	0.00242	0.00364	CcSEcCtD
Maprotiline—Increased appetite—Doxorubicin—bone cancer	0.00242	0.00363	CcSEcCtD
Maprotiline—Menopausal symptoms—Doxorubicin—bone cancer	0.00241	0.00362	CcSEcCtD
Maprotiline—Breast disorder—Methotrexate—bone cancer	0.00237	0.00356	CcSEcCtD
Maprotiline—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.00236	0.00355	CcSEcCtD
Maprotiline—Purpura—Doxorubicin—bone cancer	0.00236	0.00354	CcSEcCtD
Maprotiline—Oedema—Cisplatin—bone cancer	0.00235	0.00353	CcSEcCtD
Maprotiline—Infection—Cisplatin—bone cancer	0.00233	0.00351	CcSEcCtD
Maprotiline—Cerebrovascular accident—Doxorubicin—bone cancer	0.00232	0.00348	CcSEcCtD
Maprotiline—Ataxia—Epirubicin—bone cancer	0.00231	0.00347	CcSEcCtD
Maprotiline—Nervous system disorder—Cisplatin—bone cancer	0.0023	0.00346	CcSEcCtD
Maprotiline—Thrombocytopenia—Cisplatin—bone cancer	0.0023	0.00345	CcSEcCtD
Maprotiline—Tachycardia—Cisplatin—bone cancer	0.00229	0.00344	CcSEcCtD
Maprotiline—Skin disorder—Cisplatin—bone cancer	0.00228	0.00343	CcSEcCtD
Maprotiline—Osteoarthritis—Doxorubicin—bone cancer	0.00227	0.00341	CcSEcCtD
Maprotiline—Hyperhidrosis—Cisplatin—bone cancer	0.00227	0.00341	CcSEcCtD
Maprotiline—Liver function test abnormal—Epirubicin—bone cancer	0.00227	0.0034	CcSEcCtD
Maprotiline—Eosinophilia—Methotrexate—bone cancer	0.00224	0.00337	CcSEcCtD
Maprotiline—Orthostatic hypotension—Epirubicin—bone cancer	0.00224	0.00337	CcSEcCtD
Maprotiline—Breast disorder—Epirubicin—bone cancer	0.00222	0.00333	CcSEcCtD
Maprotiline—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.00221	0.00332	CcSEcCtD
Maprotiline—Hypotension—Cisplatin—bone cancer	0.0022	0.0033	CcSEcCtD
Maprotiline—Nortriptyline—CYP3A4—bone cancer	0.00219	0.122	CrCbGaD
Maprotiline—Muscular weakness—Epirubicin—bone cancer	0.00217	0.00325	CcSEcCtD
Maprotiline—Pancytopenia—Methotrexate—bone cancer	0.00215	0.00323	CcSEcCtD
Maprotiline—Ataxia—Doxorubicin—bone cancer	0.00214	0.00321	CcSEcCtD
Maprotiline—Dysphagia—Epirubicin—bone cancer	0.00212	0.00319	CcSEcCtD
Maprotiline—Paraesthesia—Cisplatin—bone cancer	0.00211	0.00317	CcSEcCtD
Maprotiline—Eosinophilia—Epirubicin—bone cancer	0.0021	0.00315	CcSEcCtD
Maprotiline—Liver function test abnormal—Doxorubicin—bone cancer	0.0021	0.00315	CcSEcCtD
Maprotiline—Erectile dysfunction—Methotrexate—bone cancer	0.00209	0.00314	CcSEcCtD
Maprotiline—Orthostatic hypotension—Doxorubicin—bone cancer	0.00207	0.00312	CcSEcCtD
Maprotiline—Photosensitivity reaction—Methotrexate—bone cancer	0.00207	0.00311	CcSEcCtD
Maprotiline—Breast disorder—Doxorubicin—bone cancer	0.00205	0.00308	CcSEcCtD
Maprotiline—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.00205	0.00307	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Cisplatin—bone cancer	0.00203	0.00305	CcSEcCtD
Maprotiline—Infestation NOS—Methotrexate—bone cancer	0.00202	0.00304	CcSEcCtD
Maprotiline—Infestation—Methotrexate—bone cancer	0.00202	0.00304	CcSEcCtD
Maprotiline—Drowsiness—Methotrexate—bone cancer	0.00202	0.00304	CcSEcCtD
Maprotiline—Pancytopenia—Epirubicin—bone cancer	0.00201	0.00303	CcSEcCtD
Maprotiline—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.002	0.00301	CcSEcCtD
Maprotiline—Muscular weakness—Doxorubicin—bone cancer	0.002	0.00301	CcSEcCtD
Maprotiline—Stomatitis—Methotrexate—bone cancer	0.00197	0.00296	CcSEcCtD
Maprotiline—Dysphagia—Doxorubicin—bone cancer	0.00196	0.00295	CcSEcCtD
Maprotiline—Pollakiuria—Epirubicin—bone cancer	0.00196	0.00294	CcSEcCtD
Maprotiline—Eosinophilia—Doxorubicin—bone cancer	0.00194	0.00292	CcSEcCtD
Maprotiline—Photosensitivity reaction—Epirubicin—bone cancer	0.00194	0.00291	CcSEcCtD
Maprotiline—Feeling abnormal—Cisplatin—bone cancer	0.00194	0.00291	CcSEcCtD
Maprotiline—Weight increased—Epirubicin—bone cancer	0.00193	0.0029	CcSEcCtD
Maprotiline—Weight decreased—Epirubicin—bone cancer	0.00192	0.00288	CcSEcCtD
Maprotiline—Hepatobiliary disease—Methotrexate—bone cancer	0.00191	0.00287	CcSEcCtD
Maprotiline—Infestation NOS—Epirubicin—bone cancer	0.00189	0.00284	CcSEcCtD
Maprotiline—Drowsiness—Epirubicin—bone cancer	0.00189	0.00284	CcSEcCtD
Maprotiline—Infestation—Epirubicin—bone cancer	0.00189	0.00284	CcSEcCtD
Maprotiline—Agranulocytosis—Methotrexate—bone cancer	0.00189	0.00283	CcSEcCtD
Maprotiline—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.00188	0.00282	CcSEcCtD
Maprotiline—Pancytopenia—Doxorubicin—bone cancer	0.00186	0.0028	CcSEcCtD
Maprotiline—Body temperature increased—Cisplatin—bone cancer	0.00186	0.00279	CcSEcCtD
Maprotiline—Neuropathy peripheral—Epirubicin—bone cancer	0.00185	0.00279	CcSEcCtD
Maprotiline—Stomatitis—Epirubicin—bone cancer	0.00184	0.00277	CcSEcCtD
Maprotiline—Jaundice—Epirubicin—bone cancer	0.00184	0.00277	CcSEcCtD
Maprotiline—Hepatitis—Methotrexate—bone cancer	0.00181	0.00273	CcSEcCtD
Maprotiline—Pollakiuria—Doxorubicin—bone cancer	0.00181	0.00272	CcSEcCtD
Maprotiline—Desipramine—CYP3A4—bone cancer	0.0018	0.1	CrCbGaD
Maprotiline—Urinary tract disorder—Methotrexate—bone cancer	0.00179	0.00269	CcSEcCtD
Maprotiline—Photosensitivity reaction—Doxorubicin—bone cancer	0.00179	0.00269	CcSEcCtD
Maprotiline—Hepatobiliary disease—Epirubicin—bone cancer	0.00179	0.00269	CcSEcCtD
Maprotiline—Weight increased—Doxorubicin—bone cancer	0.00179	0.00268	CcSEcCtD
Maprotiline—Urethral disorder—Methotrexate—bone cancer	0.00178	0.00267	CcSEcCtD
Maprotiline—Weight decreased—Doxorubicin—bone cancer	0.00178	0.00267	CcSEcCtD
Maprotiline—Agranulocytosis—Epirubicin—bone cancer	0.00177	0.00265	CcSEcCtD
Maprotiline—Infestation NOS—Doxorubicin—bone cancer	0.00175	0.00263	CcSEcCtD
Maprotiline—Drowsiness—Doxorubicin—bone cancer	0.00175	0.00263	CcSEcCtD
Maprotiline—Infestation—Doxorubicin—bone cancer	0.00175	0.00263	CcSEcCtD
Maprotiline—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.00174	0.00261	CcSEcCtD
Maprotiline—Erythema multiforme—Methotrexate—bone cancer	0.00172	0.00258	CcSEcCtD
Maprotiline—Neuropathy peripheral—Doxorubicin—bone cancer	0.00172	0.00258	CcSEcCtD
Maprotiline—Jaundice—Doxorubicin—bone cancer	0.00171	0.00256	CcSEcCtD
Maprotiline—Stomatitis—Doxorubicin—bone cancer	0.00171	0.00256	CcSEcCtD
Maprotiline—Hepatitis—Epirubicin—bone cancer	0.0017	0.00255	CcSEcCtD
Maprotiline—Eye disorder—Methotrexate—bone cancer	0.0017	0.00255	CcSEcCtD
Maprotiline—Tinnitus—Methotrexate—bone cancer	0.00169	0.00254	CcSEcCtD
Maprotiline—Hypoaesthesia—Epirubicin—bone cancer	0.00169	0.00254	CcSEcCtD
Maprotiline—Asthenia—Cisplatin—bone cancer	0.00169	0.00253	CcSEcCtD
Maprotiline—Cardiac disorder—Methotrexate—bone cancer	0.00168	0.00253	CcSEcCtD
Maprotiline—Urinary tract disorder—Epirubicin—bone cancer	0.00168	0.00252	CcSEcCtD
Maprotiline—Urethral disorder—Epirubicin—bone cancer	0.00166	0.0025	CcSEcCtD
Maprotiline—Hepatobiliary disease—Doxorubicin—bone cancer	0.00166	0.00249	CcSEcCtD
Maprotiline—Angiopathy—Methotrexate—bone cancer	0.00165	0.00247	CcSEcCtD
Maprotiline—Mediastinal disorder—Methotrexate—bone cancer	0.00164	0.00246	CcSEcCtD
Maprotiline—Agranulocytosis—Doxorubicin—bone cancer	0.00163	0.00245	CcSEcCtD
Maprotiline—Diarrhoea—Cisplatin—bone cancer	0.00161	0.00241	CcSEcCtD
Maprotiline—Erythema multiforme—Epirubicin—bone cancer	0.00161	0.00241	CcSEcCtD
Maprotiline—Alopecia—Methotrexate—bone cancer	0.0016	0.00241	CcSEcCtD
Maprotiline—Eye disorder—Epirubicin—bone cancer	0.00159	0.00238	CcSEcCtD
Maprotiline—Tinnitus—Epirubicin—bone cancer	0.00158	0.00238	CcSEcCtD
Maprotiline—Malnutrition—Methotrexate—bone cancer	0.00158	0.00237	CcSEcCtD
Maprotiline—Flushing—Epirubicin—bone cancer	0.00158	0.00237	CcSEcCtD
Maprotiline—Cardiac disorder—Epirubicin—bone cancer	0.00158	0.00237	CcSEcCtD
Maprotiline—Hepatitis—Doxorubicin—bone cancer	0.00157	0.00236	CcSEcCtD
Maprotiline—Hypoaesthesia—Doxorubicin—bone cancer	0.00156	0.00235	CcSEcCtD
Maprotiline—Urinary tract disorder—Doxorubicin—bone cancer	0.00155	0.00233	CcSEcCtD
Maprotiline—Dysgeusia—Methotrexate—bone cancer	0.00155	0.00232	CcSEcCtD
Maprotiline—Angiopathy—Epirubicin—bone cancer	0.00154	0.00231	CcSEcCtD
Maprotiline—Urethral disorder—Doxorubicin—bone cancer	0.00154	0.00231	CcSEcCtD
Maprotiline—Mediastinal disorder—Epirubicin—bone cancer	0.00153	0.0023	CcSEcCtD
Maprotiline—Imipramine—CYP3A4—bone cancer	0.00153	0.085	CrCbGaD
Maprotiline—Arrhythmia—Epirubicin—bone cancer	0.00152	0.00228	CcSEcCtD
Maprotiline—Alopecia—Epirubicin—bone cancer	0.0015	0.00225	CcSEcCtD
Maprotiline—Vomiting—Cisplatin—bone cancer	0.00149	0.00224	CcSEcCtD
Maprotiline—Vision blurred—Methotrexate—bone cancer	0.00149	0.00224	CcSEcCtD
Maprotiline—Erythema multiforme—Doxorubicin—bone cancer	0.00149	0.00223	CcSEcCtD
Maprotiline—Rash—Cisplatin—bone cancer	0.00148	0.00222	CcSEcCtD
Maprotiline—Dermatitis—Cisplatin—bone cancer	0.00148	0.00222	CcSEcCtD
Maprotiline—Malnutrition—Epirubicin—bone cancer	0.00148	0.00222	CcSEcCtD
Maprotiline—Eye disorder—Doxorubicin—bone cancer	0.00147	0.00221	CcSEcCtD
Maprotiline—Tinnitus—Doxorubicin—bone cancer	0.00147	0.0022	CcSEcCtD
Maprotiline—Flushing—Doxorubicin—bone cancer	0.00146	0.00219	CcSEcCtD
Maprotiline—Cardiac disorder—Doxorubicin—bone cancer	0.00146	0.00219	CcSEcCtD
Maprotiline—Tension—Epirubicin—bone cancer	0.00145	0.00218	CcSEcCtD
Maprotiline—Dysgeusia—Epirubicin—bone cancer	0.00145	0.00217	CcSEcCtD
Maprotiline—Nervousness—Epirubicin—bone cancer	0.00144	0.00216	CcSEcCtD
Maprotiline—Angiopathy—Doxorubicin—bone cancer	0.00143	0.00214	CcSEcCtD
Maprotiline—Mediastinal disorder—Doxorubicin—bone cancer	0.00142	0.00213	CcSEcCtD
Maprotiline—Leukopenia—Methotrexate—bone cancer	0.00141	0.00212	CcSEcCtD
Maprotiline—Arrhythmia—Doxorubicin—bone cancer	0.0014	0.00211	CcSEcCtD
Maprotiline—Nausea—Cisplatin—bone cancer	0.0014	0.0021	CcSEcCtD
Maprotiline—Vision blurred—Epirubicin—bone cancer	0.00139	0.00209	CcSEcCtD
Maprotiline—Alopecia—Doxorubicin—bone cancer	0.00139	0.00209	CcSEcCtD
Maprotiline—Convulsion—Methotrexate—bone cancer	0.00137	0.00206	CcSEcCtD
Maprotiline—Malnutrition—Doxorubicin—bone cancer	0.00137	0.00205	CcSEcCtD
Maprotiline—Agitation—Epirubicin—bone cancer	0.00136	0.00204	CcSEcCtD
Maprotiline—Tension—Doxorubicin—bone cancer	0.00134	0.00202	CcSEcCtD
Maprotiline—Dysgeusia—Doxorubicin—bone cancer	0.00134	0.00201	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.00134	0.00201	CcSEcCtD
Maprotiline—Nervousness—Doxorubicin—bone cancer	0.00133	0.002	CcSEcCtD
Maprotiline—Syncope—Epirubicin—bone cancer	0.00133	0.00199	CcSEcCtD
Maprotiline—Leukopenia—Epirubicin—bone cancer	0.00132	0.00199	CcSEcCtD
Maprotiline—Palpitations—Epirubicin—bone cancer	0.00131	0.00196	CcSEcCtD
Maprotiline—Confusional state—Methotrexate—bone cancer	0.0013	0.00195	CcSEcCtD
Maprotiline—Loss of consciousness—Epirubicin—bone cancer	0.0013	0.00195	CcSEcCtD
Maprotiline—Vision blurred—Doxorubicin—bone cancer	0.00129	0.00194	CcSEcCtD
Maprotiline—Convulsion—Epirubicin—bone cancer	0.00128	0.00192	CcSEcCtD
Maprotiline—Infection—Methotrexate—bone cancer	0.00128	0.00192	CcSEcCtD
Maprotiline—Hypertension—Epirubicin—bone cancer	0.00128	0.00192	CcSEcCtD
Maprotiline—Nervous system disorder—Methotrexate—bone cancer	0.00126	0.0019	CcSEcCtD
Maprotiline—Thrombocytopenia—Methotrexate—bone cancer	0.00126	0.0019	CcSEcCtD
Maprotiline—Agitation—Doxorubicin—bone cancer	0.00126	0.00189	CcSEcCtD
Maprotiline—Anxiety—Epirubicin—bone cancer	0.00125	0.00188	CcSEcCtD
Maprotiline—Skin disorder—Methotrexate—bone cancer	0.00125	0.00188	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.00125	0.00188	CcSEcCtD
Maprotiline—Hyperhidrosis—Methotrexate—bone cancer	0.00125	0.00187	CcSEcCtD
Maprotiline—Dry mouth—Epirubicin—bone cancer	0.00123	0.00185	CcSEcCtD
Maprotiline—Syncope—Doxorubicin—bone cancer	0.00123	0.00184	CcSEcCtD
Maprotiline—Leukopenia—Doxorubicin—bone cancer	0.00122	0.00184	CcSEcCtD
Maprotiline—Confusional state—Epirubicin—bone cancer	0.00122	0.00183	CcSEcCtD
Maprotiline—Palpitations—Doxorubicin—bone cancer	0.00121	0.00182	CcSEcCtD
Maprotiline—Oedema—Epirubicin—bone cancer	0.00121	0.00181	CcSEcCtD
Maprotiline—Hypotension—Methotrexate—bone cancer	0.0012	0.00181	CcSEcCtD
Maprotiline—Loss of consciousness—Doxorubicin—bone cancer	0.0012	0.00181	CcSEcCtD
Maprotiline—Infection—Epirubicin—bone cancer	0.0012	0.0018	CcSEcCtD
Maprotiline—ORM1—vertebral column—bone cancer	0.00119	0.157	CbGeAlD
Maprotiline—Shock—Epirubicin—bone cancer	0.00119	0.00178	CcSEcCtD
Maprotiline—Convulsion—Doxorubicin—bone cancer	0.00119	0.00178	CcSEcCtD
Maprotiline—Nervous system disorder—Epirubicin—bone cancer	0.00118	0.00178	CcSEcCtD
Maprotiline—Thrombocytopenia—Epirubicin—bone cancer	0.00118	0.00177	CcSEcCtD
Maprotiline—Hypertension—Doxorubicin—bone cancer	0.00118	0.00177	CcSEcCtD
Maprotiline—Tachycardia—Epirubicin—bone cancer	0.00118	0.00177	CcSEcCtD
Maprotiline—HRH1—nose—bone cancer	0.00117	0.154	CbGeAlD
Maprotiline—Skin disorder—Epirubicin—bone cancer	0.00117	0.00176	CcSEcCtD
Maprotiline—Hyperhidrosis—Epirubicin—bone cancer	0.00117	0.00175	CcSEcCtD
Maprotiline—Insomnia—Methotrexate—bone cancer	0.00117	0.00175	CcSEcCtD
Maprotiline—Anxiety—Doxorubicin—bone cancer	0.00116	0.00174	CcSEcCtD
Maprotiline—Paraesthesia—Methotrexate—bone cancer	0.00116	0.00174	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.00116	0.00174	CcSEcCtD
Maprotiline—Somnolence—Methotrexate—bone cancer	0.00115	0.00172	CcSEcCtD
Maprotiline—Dry mouth—Doxorubicin—bone cancer	0.00114	0.00171	CcSEcCtD
Maprotiline—Dyspepsia—Methotrexate—bone cancer	0.00113	0.0017	CcSEcCtD
Maprotiline—Hypotension—Epirubicin—bone cancer	0.00113	0.00169	CcSEcCtD
Maprotiline—Confusional state—Doxorubicin—bone cancer	0.00113	0.00169	CcSEcCtD
Maprotiline—Oedema—Doxorubicin—bone cancer	0.00112	0.00168	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Methotrexate—bone cancer	0.00111	0.00167	CcSEcCtD
Maprotiline—Fatigue—Methotrexate—bone cancer	0.00111	0.00167	CcSEcCtD
Maprotiline—Infection—Doxorubicin—bone cancer	0.00111	0.00167	CcSEcCtD
Maprotiline—Shock—Doxorubicin—bone cancer	0.0011	0.00165	CcSEcCtD
Maprotiline—Nervous system disorder—Doxorubicin—bone cancer	0.00109	0.00164	CcSEcCtD
Maprotiline—Thrombocytopenia—Doxorubicin—bone cancer	0.00109	0.00164	CcSEcCtD
Maprotiline—Insomnia—Epirubicin—bone cancer	0.00109	0.00164	CcSEcCtD
Maprotiline—Tachycardia—Doxorubicin—bone cancer	0.00109	0.00164	CcSEcCtD
Maprotiline—Skin disorder—Doxorubicin—bone cancer	0.00108	0.00163	CcSEcCtD
Maprotiline—Paraesthesia—Epirubicin—bone cancer	0.00108	0.00163	CcSEcCtD
Maprotiline—Hyperhidrosis—Doxorubicin—bone cancer	0.00108	0.00162	CcSEcCtD
Maprotiline—Somnolence—Epirubicin—bone cancer	0.00107	0.00161	CcSEcCtD
Maprotiline—Feeling abnormal—Methotrexate—bone cancer	0.00106	0.0016	CcSEcCtD
Maprotiline—Dyspepsia—Epirubicin—bone cancer	0.00106	0.0016	CcSEcCtD
Maprotiline—Gastrointestinal pain—Methotrexate—bone cancer	0.00105	0.00158	CcSEcCtD
Maprotiline—Hypotension—Doxorubicin—bone cancer	0.00104	0.00157	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Epirubicin—bone cancer	0.00104	0.00156	CcSEcCtD
Maprotiline—Fatigue—Epirubicin—bone cancer	0.00104	0.00156	CcSEcCtD
Maprotiline—Constipation—Epirubicin—bone cancer	0.00103	0.00155	CcSEcCtD
Maprotiline—Urticaria—Methotrexate—bone cancer	0.00102	0.00154	CcSEcCtD
Maprotiline—Body temperature increased—Methotrexate—bone cancer	0.00102	0.00153	CcSEcCtD
Maprotiline—Abdominal pain—Methotrexate—bone cancer	0.00102	0.00153	CcSEcCtD
Maprotiline—Insomnia—Doxorubicin—bone cancer	0.00101	0.00152	CcSEcCtD
Maprotiline—Paraesthesia—Doxorubicin—bone cancer	0.001	0.00151	CcSEcCtD
Maprotiline—Feeling abnormal—Epirubicin—bone cancer	0.000994	0.00149	CcSEcCtD
Maprotiline—Somnolence—Doxorubicin—bone cancer	0.000992	0.00149	CcSEcCtD
Maprotiline—Gastrointestinal pain—Epirubicin—bone cancer	0.000987	0.00148	CcSEcCtD
Maprotiline—Dyspepsia—Doxorubicin—bone cancer	0.000983	0.00148	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000964	0.00145	CcSEcCtD
Maprotiline—Fatigue—Doxorubicin—bone cancer	0.000962	0.00145	CcSEcCtD
Maprotiline—Urticaria—Epirubicin—bone cancer	0.000958	0.00144	CcSEcCtD
Maprotiline—Constipation—Doxorubicin—bone cancer	0.000955	0.00143	CcSEcCtD
Maprotiline—Abdominal pain—Epirubicin—bone cancer	0.000954	0.00143	CcSEcCtD
Maprotiline—Body temperature increased—Epirubicin—bone cancer	0.000954	0.00143	CcSEcCtD
Maprotiline—Asthenia—Methotrexate—bone cancer	0.000925	0.00139	CcSEcCtD
Maprotiline—Feeling abnormal—Doxorubicin—bone cancer	0.00092	0.00138	CcSEcCtD
Maprotiline—Gastrointestinal pain—Doxorubicin—bone cancer	0.000913	0.00137	CcSEcCtD
Maprotiline—Pruritus—Methotrexate—bone cancer	0.000912	0.00137	CcSEcCtD
Maprotiline—Urticaria—Doxorubicin—bone cancer	0.000887	0.00133	CcSEcCtD
Maprotiline—Body temperature increased—Doxorubicin—bone cancer	0.000882	0.00133	CcSEcCtD
Maprotiline—Abdominal pain—Doxorubicin—bone cancer	0.000882	0.00133	CcSEcCtD
Maprotiline—Diarrhoea—Methotrexate—bone cancer	0.000882	0.00132	CcSEcCtD
Maprotiline—HTR7—cranial nerve—bone cancer	0.00088	0.115	CbGeAlD
Maprotiline—Asthenia—Epirubicin—bone cancer	0.000866	0.0013	CcSEcCtD
Maprotiline—Pruritus—Epirubicin—bone cancer	0.000854	0.00128	CcSEcCtD
Maprotiline—Dizziness—Methotrexate—bone cancer	0.000853	0.00128	CcSEcCtD
Maprotiline—Diarrhoea—Epirubicin—bone cancer	0.000826	0.00124	CcSEcCtD
Maprotiline—Vomiting—Methotrexate—bone cancer	0.00082	0.00123	CcSEcCtD
Maprotiline—Rash—Methotrexate—bone cancer	0.000813	0.00122	CcSEcCtD
Maprotiline—Dermatitis—Methotrexate—bone cancer	0.000812	0.00122	CcSEcCtD
Maprotiline—Headache—Methotrexate—bone cancer	0.000808	0.00121	CcSEcCtD
Maprotiline—Asthenia—Doxorubicin—bone cancer	0.000801	0.0012	CcSEcCtD
Maprotiline—Dizziness—Epirubicin—bone cancer	0.000798	0.0012	CcSEcCtD
Maprotiline—Pruritus—Doxorubicin—bone cancer	0.00079	0.00119	CcSEcCtD
Maprotiline—HTR2A—trigeminal nerve—bone cancer	0.00077	0.101	CbGeAlD
Maprotiline—Vomiting—Epirubicin—bone cancer	0.000767	0.00115	CcSEcCtD
Maprotiline—Nausea—Methotrexate—bone cancer	0.000766	0.00115	CcSEcCtD
Maprotiline—Diarrhoea—Doxorubicin—bone cancer	0.000764	0.00115	CcSEcCtD
Maprotiline—Rash—Epirubicin—bone cancer	0.000761	0.00114	CcSEcCtD
Maprotiline—Dermatitis—Epirubicin—bone cancer	0.00076	0.00114	CcSEcCtD
Maprotiline—Headache—Epirubicin—bone cancer	0.000756	0.00114	CcSEcCtD
Maprotiline—Dizziness—Doxorubicin—bone cancer	0.000738	0.00111	CcSEcCtD
Maprotiline—Nausea—Epirubicin—bone cancer	0.000717	0.00108	CcSEcCtD
Maprotiline—Vomiting—Doxorubicin—bone cancer	0.00071	0.00107	CcSEcCtD
Maprotiline—Rash—Doxorubicin—bone cancer	0.000704	0.00106	CcSEcCtD
Maprotiline—Dermatitis—Doxorubicin—bone cancer	0.000703	0.00106	CcSEcCtD
Maprotiline—Headache—Doxorubicin—bone cancer	0.000699	0.00105	CcSEcCtD
Maprotiline—Nausea—Doxorubicin—bone cancer	0.000663	0.000996	CcSEcCtD
Maprotiline—HTR2A—cranial nerve—bone cancer	0.000549	0.072	CbGeAlD
Maprotiline—HTR2A—vertebral column—bone cancer	0.000538	0.0706	CbGeAlD
Maprotiline—HTR2A—hindlimb—bone cancer	0.000462	0.0607	CbGeAlD
Maprotiline—HTR2A—appendage—bone cancer	0.000397	0.0521	CbGeAlD
Maprotiline—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.000273	0.000886	CbGpPWpGaD
Maprotiline—HTR7—Circadian rythm related genes—TP53—bone cancer	0.000268	0.000868	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—GRM1—bone cancer	0.000266	0.000861	CbGpPWpGaD
Maprotiline—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.000264	0.000856	CbGpPWpGaD
Maprotiline—DRD2—Circadian rythm related genes—JUN—bone cancer	0.000264	0.000855	CbGpPWpGaD
Maprotiline—CHRM4—Signaling by GPCR—IL3—bone cancer	0.000263	0.000852	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—NDUFA12—bone cancer	0.000262	0.000848	CbGpPWpGaD
Maprotiline—CHRM1—Circadian rythm related genes—JUN—bone cancer	0.000258	0.000837	CbGpPWpGaD
Maprotiline—CHRM1—Regulation of Actin Cytoskeleton—EGFR—bone cancer	0.000258	0.000836	CbGpPWpGaD
Maprotiline—CHRM3—Regulation of Actin Cytoskeleton—EGFR—bone cancer	0.000257	0.000833	CbGpPWpGaD
Maprotiline—CHRM2—Regulation of Actin Cytoskeleton—EGFR—bone cancer	0.000255	0.000825	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—GRM1—bone cancer	0.000255	0.000825	CbGpPWpGaD
Maprotiline—CHRM5—Signaling by GPCR—IL3—bone cancer	0.000252	0.000816	CbGpPWpGaD
Maprotiline—HTR2C—GPCR downstream signaling—GNA11—bone cancer	0.000249	0.000808	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—SMO—bone cancer	0.000248	0.000802	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—GRM4—bone cancer	0.000239	0.000776	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—RGS1—bone cancer	0.000239	0.000776	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—NT5C3A—bone cancer	0.00023	0.000746	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—GNA11—bone cancer	0.000226	0.000734	CbGpPWpGaD
Maprotiline—HTR2C—GPCR downstream signaling—IL3—bone cancer	0.000226	0.000732	CbGpPWpGaD
Maprotiline—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.000223	0.000722	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—NDUFA12—bone cancer	0.000222	0.000718	CbGpPWpGaD
Maprotiline—DRD2—GPCR downstream signaling—GNA11—bone cancer	0.00022	0.000713	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—SMO—bone cancer	0.000218	0.000708	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—NT5C3A—bone cancer	0.000217	0.000703	CbGpPWpGaD
Maprotiline—HTR2A—GPCR downstream signaling—GNA11—bone cancer	0.000216	0.000702	CbGpPWpGaD
Maprotiline—HRH1—GPCR downstream signaling—GNA11—bone cancer	0.000216	0.0007	CbGpPWpGaD
Maprotiline—CHRM1—GPCR downstream signaling—GNA11—bone cancer	0.000215	0.000698	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—SMO—bone cancer	0.000215	0.000697	CbGpPWpGaD
Maprotiline—CHRM3—GPCR downstream signaling—GNA11—bone cancer	0.000215	0.000696	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—SMO—bone cancer	0.000214	0.000695	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—SMO—bone cancer	0.000214	0.000693	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—SMO—bone cancer	0.000213	0.000691	CbGpPWpGaD
Maprotiline—CHRM2—GPCR downstream signaling—GNA11—bone cancer	0.000213	0.000689	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—GRM4—bone cancer	0.000211	0.000685	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—RGS1—bone cancer	0.000211	0.000685	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—SMO—bone cancer	0.000211	0.000684	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—GRM4—bone cancer	0.000208	0.000674	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—RGS1—bone cancer	0.000208	0.000674	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—GRM1—bone cancer	0.000208	0.000673	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—GRM4—bone cancer	0.000207	0.000672	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—RGS1—bone cancer	0.000207	0.000672	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—GRM4—bone cancer	0.000207	0.00067	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—RGS1—bone cancer	0.000207	0.00067	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—GRM4—bone cancer	0.000206	0.000668	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—RGS1—bone cancer	0.000206	0.000668	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—IL3—bone cancer	0.000205	0.000665	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—GRM4—bone cancer	0.000204	0.000661	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—RGS1—bone cancer	0.000204	0.000661	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—GNA11—bone cancer	0.0002	0.000647	CbGpPWpGaD
Maprotiline—DRD2—GPCR downstream signaling—IL3—bone cancer	0.000199	0.000646	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—SMO—bone cancer	0.000198	0.000643	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—GNA11—bone cancer	0.000197	0.000637	CbGpPWpGaD
Maprotiline—HTR2A—GPCR downstream signaling—IL3—bone cancer	0.000196	0.000636	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—GNA11—bone cancer	0.000196	0.000636	CbGpPWpGaD
Maprotiline—HRH1—GPCR downstream signaling—IL3—bone cancer	0.000196	0.000635	CbGpPWpGaD
Maprotiline—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.000196	0.000634	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—GNA11—bone cancer	0.000196	0.000634	CbGpPWpGaD
Maprotiline—CHRM1—GPCR downstream signaling—IL3—bone cancer	0.000195	0.000633	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—GNA11—bone cancer	0.000195	0.000632	CbGpPWpGaD
Maprotiline—CHRM3—GPCR downstream signaling—IL3—bone cancer	0.000195	0.000631	CbGpPWpGaD
Maprotiline—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.000193	0.000627	CbGpPWpGaD
Maprotiline—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.000193	0.000626	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—GNA11—bone cancer	0.000193	0.000625	CbGpPWpGaD
Maprotiline—CHRM2—GPCR downstream signaling—IL3—bone cancer	0.000193	0.000624	CbGpPWpGaD
Maprotiline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.000192	0.000624	CbGpPWpGaD
Maprotiline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.000192	0.000622	CbGpPWpGaD
Maprotiline—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.000189	0.000612	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—SMO—bone cancer	0.000187	0.000607	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—NT5C3A—bone cancer	0.000184	0.000595	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—GRM1—bone cancer	0.000183	0.000594	CbGpPWpGaD
Maprotiline—HTR7—connective tissue—bone cancer	0.000182	0.0238	CbGeAlD
Maprotiline—HTR7—Signaling Pathways—GNA11—bone cancer	0.000181	0.000588	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—IL3—bone cancer	0.000181	0.000587	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—GRM1—bone cancer	0.00018	0.000584	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—GRM1—bone cancer	0.00018	0.000583	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—SMO—bone cancer	0.000179	0.000581	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—GRM1—bone cancer	0.000179	0.000581	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—GRM1—bone cancer	0.000179	0.000579	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—IL3—bone cancer	0.000178	0.000578	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—IL3—bone cancer	0.000178	0.000576	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—IL3—bone cancer	0.000177	0.000574	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—GRM1—bone cancer	0.000177	0.000573	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—IL3—bone cancer	0.000177	0.000573	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—IL3—bone cancer	0.000175	0.000567	CbGpPWpGaD
Maprotiline—DRD2—Circadian rythm related genes—TP53—bone cancer	0.000174	0.000565	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—GNA11—bone cancer	0.000171	0.000555	CbGpPWpGaD
Maprotiline—CHRM1—Circadian rythm related genes—TP53—bone cancer	0.00017	0.000552	CbGpPWpGaD
Maprotiline—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	0.00017	0.000551	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—ATF1—bone cancer	0.000169	0.000546	CbGpPWpGaD
Maprotiline—ORM1—bone marrow—bone cancer	0.000167	0.0219	CbGeAlD
Maprotiline—ORM1—spinal cord—bone cancer	0.000166	0.0218	CbGeAlD
Maprotiline—HTR7—Signaling Pathways—IL3—bone cancer	0.000164	0.000533	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—GNA11—bone cancer	0.000164	0.000532	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—ATF1—bone cancer	0.000159	0.000516	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—ENO2—bone cancer	0.000159	0.000515	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—IL3—bone cancer	0.000155	0.000503	CbGpPWpGaD
Maprotiline—SLC6A3—spinal cord—bone cancer	0.000155	0.0203	CbGeAlD
Maprotiline—CHRM5—Signaling Pathways—ATF1—bone cancer	0.000153	0.000494	CbGpPWpGaD
Maprotiline—HTR2C—spinal cord—bone cancer	0.00015	0.0196	CbGeAlD
Maprotiline—CHRM5—Signaling Pathways—IL3—bone cancer	0.000149	0.000482	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—DHFR—bone cancer	0.000147	0.000477	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—SMO—bone cancer	0.000146	0.000474	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—TGFBR2—bone cancer	0.000141	0.000456	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—GNA11—bone cancer	0.000138	0.000446	CbGpPWpGaD
Maprotiline—HRH1—connective tissue—bone cancer	0.000136	0.0178	CbGeAlD
Maprotiline—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	0.000134	0.000434	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—GNA11—bone cancer	0.000134	0.000433	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—TGFBR2—bone cancer	0.000133	0.00043	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—IGF1R—bone cancer	0.000132	0.000429	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—SMO—bone cancer	0.000129	0.000418	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—TGFBR2—bone cancer	0.000127	0.000412	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—SMO—bone cancer	0.000127	0.000411	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—SMO—bone cancer	0.000127	0.000411	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—SMO—bone cancer	0.000126	0.000409	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—SMO—bone cancer	0.000126	0.000408	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—IGF1R—bone cancer	0.000125	0.000405	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—CYP3A4—bone cancer	0.000125	0.000405	CbGpPWpGaD
Maprotiline—HTR7—tendon—bone cancer	0.000125	0.0164	CbGeAlD
Maprotiline—CHRM2—Signaling Pathways—SMO—bone cancer	0.000125	0.000404	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—ATF1—bone cancer	0.000124	0.000403	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—IL3—bone cancer	0.000121	0.000393	CbGpPWpGaD
Maprotiline—HTR7—spinal cord—bone cancer	0.00012	0.0158	CbGeAlD
Maprotiline—CHRM5—Signaling Pathways—IGF1R—bone cancer	0.00012	0.000388	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—GNA11—bone cancer	0.000118	0.000382	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—GNA11—bone cancer	0.000116	0.000376	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—GNA11—bone cancer	0.000116	0.000376	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—GNA11—bone cancer	0.000115	0.000374	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—GNA11—bone cancer	0.000115	0.000373	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—GNA11—bone cancer	0.000114	0.000369	CbGpPWpGaD
Maprotiline—HTR2A—connective tissue—bone cancer	0.000113	0.0149	CbGeAlD
Maprotiline—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	0.000112	0.000364	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—ATF1—bone cancer	0.00011	0.000356	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—ATF1—bone cancer	0.000108	0.00035	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—ATF1—bone cancer	0.000108	0.000349	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—ATF1—bone cancer	0.000107	0.000348	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—ATF1—bone cancer	0.000107	0.000347	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—IL3—bone cancer	0.000107	0.000347	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—GSTP1—bone cancer	0.000107	0.000346	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—ATF1—bone cancer	0.000106	0.000344	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—IL3—bone cancer	0.000105	0.000341	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—IL3—bone cancer	0.000105	0.00034	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—IL3—bone cancer	0.000105	0.000339	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—IL3—bone cancer	0.000104	0.000338	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—TGFBR2—bone cancer	0.000104	0.000336	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—IL3—bone cancer	0.000103	0.000335	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—ENO2—bone cancer	0.000101	0.000327	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—IGF1R—bone cancer	9.76e-05	0.000316	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—KIT—bone cancer	9.6e-05	0.000311	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—ENO2—bone cancer	9.5e-05	0.000308	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—DHFR—bone cancer	9.35e-05	0.000303	CbGpPWpGaD
Maprotiline—HRH1—tendon—bone cancer	9.32e-05	0.0122	CbGeAlD
Maprotiline—DRD2—Signaling Pathways—TGFBR2—bone cancer	9.15e-05	0.000297	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—KIT—bone cancer	9.06e-05	0.000294	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—BRAF—bone cancer	9.02e-05	0.000292	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—TGFBR2—bone cancer	9e-05	0.000292	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—TGFBR2—bone cancer	8.98e-05	0.000291	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—TGFBR2—bone cancer	8.96e-05	0.00029	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—TGFBR2—bone cancer	8.93e-05	0.000289	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—TGFBR2—bone cancer	8.84e-05	0.000287	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—DHFR—bone cancer	8.81e-05	0.000285	CbGpPWpGaD
Maprotiline—HTR7—Signaling by GPCR—EGFR—bone cancer	8.74e-05	0.000283	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—GNA11—bone cancer	8.74e-05	0.000283	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—KIT—bone cancer	8.68e-05	0.000281	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—IGF1R—bone cancer	8.61e-05	0.000279	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—BRAF—bone cancer	8.52e-05	0.000276	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—IGF1R—bone cancer	8.47e-05	0.000275	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—IGF1R—bone cancer	8.45e-05	0.000274	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—IGF1R—bone cancer	8.43e-05	0.000273	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—IGF1R—bone cancer	8.4e-05	0.000272	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—IGF1R—bone cancer	8.32e-05	0.00027	CbGpPWpGaD
Maprotiline—CHRM4—Signaling by GPCR—EGFR—bone cancer	8.26e-05	0.000268	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—GNA11—bone cancer	8.23e-05	0.000267	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—BRAF—bone cancer	8.16e-05	0.000264	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—ENO2—bone cancer	8.04e-05	0.000261	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—CYP3A4—bone cancer	7.92e-05	0.000257	CbGpPWpGaD
Maprotiline—CHRM5—Signaling by GPCR—EGFR—bone cancer	7.91e-05	0.000256	CbGpPWpGaD
Maprotiline—HTR2A—tendon—bone cancer	7.78e-05	0.0102	CbGeAlD
Maprotiline—HTR7—Signaling Pathways—MDM2—bone cancer	7.56e-05	0.000245	CbGpPWpGaD
Maprotiline—HTR2A—spinal cord—bone cancer	7.5e-05	0.00985	CbGeAlD
Maprotiline—CYP2D6—Metabolism—CYP3A4—bone cancer	7.46e-05	0.000242	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—DHFR—bone cancer	7.46e-05	0.000242	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—MDM2—bone cancer	7.14e-05	0.000231	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—KIT—bone cancer	7.08e-05	0.000229	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—GNA11—bone cancer	6.97e-05	0.000226	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—MDM2—bone cancer	6.84e-05	0.000222	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—GSTP1—bone cancer	6.77e-05	0.00022	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—BRAF—bone cancer	6.65e-05	0.000216	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—JUN—bone cancer	6.57e-05	0.000213	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—EGFR—bone cancer	6.45e-05	0.000209	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—MMP9—bone cancer	6.39e-05	0.000207	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—GSTP1—bone cancer	6.38e-05	0.000207	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—CYP3A4—bone cancer	6.32e-05	0.000205	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	6.29e-05	0.000204	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—KIT—bone cancer	6.24e-05	0.000202	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—JUN—bone cancer	6.2e-05	0.000201	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—KIT—bone cancer	6.14e-05	0.000199	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—KIT—bone cancer	6.13e-05	0.000199	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—KIT—bone cancer	6.11e-05	0.000198	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—KIT—bone cancer	6.09e-05	0.000197	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—MMP9—bone cancer	6.04e-05	0.000196	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—KIT—bone cancer	6.03e-05	0.000195	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—JUN—bone cancer	5.94e-05	0.000193	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—BRAF—bone cancer	5.87e-05	0.00019	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—MMP9—bone cancer	5.78e-05	0.000187	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—BRAF—bone cancer	5.77e-05	0.000187	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—BRAF—bone cancer	5.76e-05	0.000187	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—BRAF—bone cancer	5.74e-05	0.000186	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—BRAF—bone cancer	5.73e-05	0.000186	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—EGFR—bone cancer	5.69e-05	0.000184	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—BRAF—bone cancer	5.67e-05	0.000184	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—EGFR—bone cancer	5.6e-05	0.000181	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—EGFR—bone cancer	5.59e-05	0.000181	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—MDM2—bone cancer	5.57e-05	0.000181	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—EGFR—bone cancer	5.57e-05	0.00018	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—EGFR—bone cancer	5.55e-05	0.00018	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—PTGS2—bone cancer	5.53e-05	0.000179	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—EGFR—bone cancer	5.5e-05	0.000178	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—GSTP1—bone cancer	5.41e-05	0.000175	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—EGFR—bone cancer	5.17e-05	0.000167	CbGpPWpGaD
Maprotiline—ABCB1—bone marrow—bone cancer	4.94e-05	0.00648	CbGeAlD
Maprotiline—ABCB1—spinal cord—bone cancer	4.92e-05	0.00645	CbGeAlD
Maprotiline—DRD2—Signaling Pathways—MDM2—bone cancer	4.92e-05	0.000159	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—EGFR—bone cancer	4.88e-05	0.000158	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—JUN—bone cancer	4.84e-05	0.000157	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MDM2—bone cancer	4.84e-05	0.000157	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MDM2—bone cancer	4.83e-05	0.000156	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MDM2—bone cancer	4.81e-05	0.000156	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MDM2—bone cancer	4.8e-05	0.000155	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MDM2—bone cancer	4.75e-05	0.000154	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—MMP9—bone cancer	4.71e-05	0.000153	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—EGFR—bone cancer	4.67e-05	0.000151	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—TP53—bone cancer	4.34e-05	0.000141	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—JUN—bone cancer	4.27e-05	0.000139	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—JUN—bone cancer	4.21e-05	0.000136	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—JUN—bone cancer	4.2e-05	0.000136	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—JUN—bone cancer	4.18e-05	0.000136	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—JUN—bone cancer	4.17e-05	0.000135	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MMP9—bone cancer	4.16e-05	0.000135	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—JUN—bone cancer	4.13e-05	0.000134	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—TP53—bone cancer	4.1e-05	0.000133	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MMP9—bone cancer	4.09e-05	0.000133	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MMP9—bone cancer	4.08e-05	0.000132	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MMP9—bone cancer	4.07e-05	0.000132	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MMP9—bone cancer	4.06e-05	0.000131	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MMP9—bone cancer	4.02e-05	0.00013	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—TP53—bone cancer	3.92e-05	0.000127	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—EGFR—bone cancer	3.81e-05	0.000123	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PTGS2—bone cancer	3.51e-05	0.000114	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—EGFR—bone cancer	3.36e-05	0.000109	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PTGS2—bone cancer	3.31e-05	0.000107	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—EGFR—bone cancer	3.31e-05	0.000107	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—EGFR—bone cancer	3.3e-05	0.000107	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—EGFR—bone cancer	3.29e-05	0.000107	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—EGFR—bone cancer	3.28e-05	0.000106	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—EGFR—bone cancer	3.25e-05	0.000105	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—TP53—bone cancer	3.2e-05	0.000104	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—TP53—bone cancer	2.82e-05	9.14e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PTGS2—bone cancer	2.8e-05	9.08e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—TP53—bone cancer	2.78e-05	9e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—TP53—bone cancer	2.77e-05	8.98e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—TP53—bone cancer	2.76e-05	8.95e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—TP53—bone cancer	2.75e-05	8.92e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—TP53—bone cancer	2.73e-05	8.83e-05	CbGpPWpGaD
